Overview of KAHF Technology 1: A solution for early stage Cancer Patients and Metastatic Patients
Targeting the KAHF receptor has demonstrated metastasis inhibition in early-stage Pancreatic Ductal Adenocarcinoma (PDAC), elimination of disseminated micro-metastatic cells, and increased sensitivity of hard-to-treat metastatic tumors to standard-of-care therapies- all supported by extensive preclinical data. Development of a therapeutic antibody, Anti-KAHF Monoclonal Antibody against this receptor is underway.
Technology 2: Targeting a dormancy-driver Transcription Factor in PDAC by leveraging Dicer substrate siRNA (DsiRNA) Technology
Targeting our novel transcription factor that regulates the dormancy program of pancreatic cancer cells has shown promising results in reactivating and eliminating these cells, significantly reducing relapse risk in mouse models. This transcription factor promotes cancer cell dormancy by modulating MHC levels, and its inhibition awakens dormant tumors, making them visible to immune cells and boosting immune infiltration in otherwise immunologically cold tumors. Building on this discovery, we have designed a Dicer-substrate siRNA technology to target this transcription factor and advance this approach toward clinical application.
Image source: IDT